Skip to content Skip to footer
Spotlight Interview_Rahul Mittal

Reuters Pharma USA 2025: Post-Conference Talks featuring Rahul Mittal

Brimming with insightful panel discussions, presentations on disruptive technologies, and illuminating real-world evidence shaping the healthcare landscape now and then, the two-day Reuters event celebrated pharmaceutical innovation and fresh perspectives pouring into the interactive sessions.In the panel discussion at Reuters Pharma USA 2025, Rahul Mittal outlined ways to enhance patient centricity and engagement. Rahul…

Read more

Spotlight Interview_Heba Nowyhed

CXO Talks: Heba Nowyhed from Arcellx in a Candid Conversation with PharmaShots

CAR T-cell therapies hold a promising foothold in addressing unmet healthcare needs. Arcellx, a clinical-stage biotech company, is steadfastly exploring the potential of cell therapy in RRMM and generalized myasthenia gravis patients with its lead asset anito-cel. During presentations at ASH, anito-cel demonstrated no delayed neurotoxicity in both P-1 and pivotal P-II clinical trials for multiple myeloma.…

Read more

Spotlight Interview_T.J.Sharpe

Reuters Pharma USA 2025: Pre Conference Talks featuring T.J. Sharpe

With breakthrough discoveries addressing patients' unmet needs, caregivers, decision-makers, and advocacy groups have made great strides towards bringing patient experience to the mainstream. Today's guest is TJ Sharpe, a Patient Insights Expert and Stage-IV Melanoma survivor. In his topic "Complicating is easy, Simplifying is Difficult, the personalized patient experience", T.J. will shed light on patient…

Read more

Reuters Events Pharma USA 2025

Reuters Events: Pharma USA 2025

Where disruption meets direction  In the past year, pharma has witnessed disruption in the external environment and internal restructure. We’ve reorganized for patients and customers – but it’s one thing to change a job title, another to transform outcomes.But how do you plan for the next wave of change across technology, regulations and expectations?For over…

Read more